Advantage of sorafenib combined with radiofrequency ablation for treatment of hepatocellular carcinoma
Advantage of sorafenib combined with radiofrequency ablation for treatment of hepatocellular carcinoma
复制标题
DOI：
10.5301/tj.5000585
复制
发表时间：
2017-05-01
期刊：
影响因子：
--
通讯作者：
Wu, Yulian
中科院分区：
文献类型：
--
作者：
Tang, Zhe;Kang, Muxing;Wu, Yulian
背景：肝细胞癌（HCC）是世界范围内的主要死亡原因。在可用的手术和非手术治疗中，射频消融（RFA）和索拉非尼已被证明具有疗效。方法：在小鼠肝癌模型中，通过肿瘤大小、射频消融诱导的坏死面积、肿瘤大小、（氯化三苯基四唑染色），微血管密度（MVD; 4 '，6-二脒基-2-苯基吲哚和抗CD 31抗体染色）和肿瘤灌注结果：在给予80和40 mg/kg索拉非尼的小鼠中，RFA诱导的坏死面积分别为80.98 +/- 9.14和69.49 +/- 7.46 mm（2），而对照组仅为57.29 ± 3.39 mm（2）。索拉非尼也减少了肿瘤体积和增强RFA诱导的肿瘤破坏的剂量依赖性的方式，并减少了MVD和肿瘤perfusion.Conclusions：我们的研究结果表明，结合RFA索拉非尼治疗肝癌的潜在作用。索拉非尼可能通过其血管生成抑制作用提高RFA效率。
Background: Hepatocellular carcinoma (HCC) is a leading cause of death worldwide. Among the surgical and nonsurgical treatments available, radiofrequency ablation (RFA) and sorafenib have been shown to have efficacy. There is little evidence whether combination of these therapies would have additional benefits.Methods: In a mouse model of HCC, effects of sorafenib were determined by tumor size, RFA-induced necrosis area (triphenyltetrazolium chloride staining), microvascular density (MVD; 4', 6-diamidino-2-phenylindole and anti-CD31 antibody staining), and tumor perfusion (magnetic resonance imaging).Results: The RFA-induced necrosis area was 80.98 +/- 9.14 and 69.49 +/- 7.46 mm(2) in mice administered 80 and 40 mg/kg sorafenib, respectively, but only 57.29 +/- 3.39 mm(2) in controls. Sorafenib also reduced tumor volume and enhanced RFA-induced tumor destruction in a dose-dependent manner, and reduced both MVD and tumor perfusion.Conclusions: The results of our study suggest a potential role for combining RFA with sorafenib for treatment of HCC. Sorafenib could enhance RFA efficiency, possibly through its angiogenesis suppressive effects.